5 of 6 Doctors: Pentagon’s Testosterone Screening Could Spur TRT Demand Without Trials

For the biotech and pharmaceutical sector, defense health policy rarely drives market-moving news—but Secretary Hegseth’s testosterone screening order changes that equation. Companies like telehealth platform Rugiet stand to gain from a sudden, government-led funnel of younger men into the TRT ecosystem. Yet the near-unanimous expert opinion that the evidence is missing raises a red flag: without data, the policy could be short-lived or invite rigorous FDA reevaluation of TRT safety in asymptomatic populations.

The U.S. Department of Defense has ignited a fierce debate among medical experts after Secretary Pete Hegseth ordered annual testosterone-deficiency screening for all active-duty and reserve service members aged 30 and older, framing the mandate as a key to maintaining combat readiness. The directive, announced in mid-July 2026, is the latest in a series of controversial health policy moves by the Trump administration's Pentagon leadership, and is immediately being met with widespread skepticism from men's health specialists. Five of six experts contacted by Reuters said the evidence does not support population-wide screening, and four explicitly stated there is no solid data linking such testing to improved military performance.

“

Companies like telehealth platform Rugiet stand to gain from a sudden, government-led funnel of younger men into the TRT ecosystem.

Hegseth's rationale is that soldiers need optimal testosterone levels "to operate at their absolute best" and that the screening, coupled with voluntary treatment advice, would boost resilience, longevity, and readiness. Yet the medical community responds that testosterone-replacement therapy (TRT) has only demonstrated benefits in symptomatic men with clinically low testosterone, not in asymptomatic screenings. Dr. Kevin McVary, a urologist on the advisory board of telehealth platform Rugiet, noted that while patients report improvements in alertness and stamina, "the evidence is not concrete." The distinction between treating symptomatic hypogonadism and screening an entire population is critical: the former follows established clinical guidelines, the latter lacks any analogous endorsement from major medical societies.

The potential harms are significant. Inappropriate testosterone prescribing can lead to polycythemia, cardiovascular events, and infertility—a particularly acute risk for younger service members who may later wish to start families. Infertility is already a sensitive issue in the military, and service members have previously voiced concerns about reproductive health impacts from deployments and other exposures. Introducing a program that could inadvertently sterilize otherwise healthy soldiers would severely undermine morale and trust in the medical system. Moreover, the cost of universal screening and subsequent consultations, lab work, and possible lifelong TRT would pose a substantial budgetary burden at a time when defense readiness dollars are under intense scrutiny.

Adding a corporate dimension, Dr. McVary’s affiliation with Rugiet—a telehealth company that directly profits from TRT prescriptions—raises conflict-of-interest questions even as he voices caution. The article notes Hegseth's order would channel service members toward advice to make treatment decisions, potentially funneling patients into the TRT marketplace. Rugiet and similar platforms could see a surge in customer inquiries, transforming a military policy into a de facto driver of consumer demand for a therapy with an uncertain risk-benefit profile in this context.

The screening mandate does not exist in isolation. It follows Hegseth’s reversal of the military’s long-standing flu vaccine mandate—a decision quickly walked back after a severe flu outbreak—and the Department of Health and Human Services’ removal of 17 members from its vaccine advisory panel and alteration of vaccine recommendations. These moves collectively signal a broader departure from evidence-based medical policies, often replacing them with political or ideological imperatives. The testosterone screening order fits this pattern: a top-down directive that bypasses normal scientific vetting, leaving installation-level medical officers to implement a program they may view as unsupported and potentially dangerous.